Fixed drug eruption caused by etoricoxib - 2 cases confirmed by patch testing

Contact Dermatitis

Volumn 64, Issue 2, 2011, Pages 118-120

  Andrade, Pedro ^a   Gonãalo, Margarida ^a  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

celecoxib; etoricoxib; fixed drug eruption; NSAID; patch tests

Indexed keywords

ALLERGEN; CELECOXIB; DICLOFENAC; ETORICOXIB; IBUPROFEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CASE REPORT; FEMALE; FEVER; FIXED DRUG ERUPTION; HUMAN; HYPERPIGMENTATION; OSTEOARTHRITIS; PAIN; PATCH TEST;

AGED; CYCLOOXYGENASE 2 INHIBITORS; DRUG ERUPTIONS; FEMALE; HUMANS; MIDDLE AGED; PATCH TESTS; PYRIDINES; SULFONES;

EID: 78651277109     PISSN: 01051873     EISSN: 16000536     Source Type: Journal    
DOI: 10.1111/j.1600-0536.2010.01847.x     Document Type: Article

References (15)

1. Oliveira H S, GonÃalo M, Reis J P, Figueiredo A., Fixed drug eruption to piroxicam. Positive patch tests with cross-sensitivity to tenoxicam. J Dermatol Treat 1999: 10: 209-212.
2. Cordeiro M R, GonÃalo M, Fernandes B, Oliveira H, Figueiredo A., Positive lesional patch tests in fixed drug eruptions from nimesulide. Contact Dermatitis 2000: 43: 307.
3. Marina S D, Vesta K S, Ripley T L., Etoricoxib: a highly selective COX-2 inhibitor. Ann Pharmacother 2005: 39: 854-862.
4. Matsumoto A K, Cavanaugh P F Jr., Etoricoxib. Drugs Today (Barc) 2004: 40: 395-414.
5. Atzori L, Pinna A L, Pau M, Aste N, Zucca M, Ferreli C., Adverse cutaneous reactions to selective cyclooxygenase 2 inhibitors: experience of an Italian drug-surveillance center. J Cutan Med Surg 2006: 10: 31-35.
6. Layton D, Marshall V, Boshier A, Friedmann P, Shakir S A., Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England. Drug Saf 2006: 29: 687-689.
7. Nettis E, Colanardi M C, Ferrannini A, Vacca A, Tursi A., Short-term tolerability of etoricoxib in patients with cutaneous hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2005: 95: 438-442. (Pubitemid 41688505)
8. Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A., Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema. Ann Allergy Asthma Immunol 2005: 95: 154-158.
9. Thirion L, Nikkels A F, Piérard G E., Etoricoxib-induced erythema-multiforme-like eruption. Dermatology 2008: 216: 227-228.
10. Mäkelä L, Lammintausta K., Etoricoxib- induced acute generalized exanthematous pustulosis. Acta Derm Venereol 2008: 88: 200-201.
11. Augustine M, Sharma P, Stephen J, Jayaseelan E., Fixed drug eruption and generalised erythema following etoricoxib. Indian J Dermatol Venereol Leprol 2006: 72: 307-309.
12. Duarte A F, Correia O, Azevedo R, Palmares M D, Delgado L., Bullous fixed drug eruption to etoricoxib-further evidence of intraepidermal CD8+ T cell involvement. Eur J Dermatol 2010: 20: 236-238.
13. Verbeiren S, Morant C, Charlanne H, Ajebbar K, Caron J, Modiano P., Celecoxib induced toxiderma with positive patch-test. Ann Dermatol Venereol 2002: 129: 203-205.
14. MarquÃs S, Milpied B, Foulc P, Barbarot S, Cassagnau E, Stalder J F., Severe cutaneous drug reactions to celecoxib (Celebrex). Ann Dermatol Venereol 2003: 130: 1051-1055.
15. Alonso J C, Ortega J D, Gonzalo M J., Cutaneous reaction to oral celecoxib with positive patch test. Contact Dermatitis 2004: 50: 48-49.